Sign up
Log in
Kailera Therapeutics names Kathleen Tregoning chief corporate affairs officer
Share
Listen to the news
Kailera Therapeutics names Kathleen Tregoning chief corporate affairs officer
  • Kailera Therapeutics appointed Kathleen Tregoning as chief corporate affairs officer as it advances late-stage obesity trials.
  • Tregoning previously served as chief corporate affairs officer and head of commercial strategy at Cerevel Therapeutics before its 2024 sale to AbbVie.
  • She was executive vice president of external affairs at Sanofi, following more than a decade at Biogen, ending as senior vice president of corporate affairs.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kailera Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606290730PRIMZONEFULLFEED9753316) on June 29, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
Terms of Service·Privacy Policy·Data Disclaimer
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved